Drug profile · INN
zafirlukast
ZAFIRLUKAST
zafirlukast (ZAFIRLUKAST) is a cysteinyl leukotriene receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — zafirlukast
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
zafirlukast (ZAFIRLUKAST) is a cysteinyl leukotriene receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cysteinyl leukotriene receptor 1 antagonist
Primary target: Cysteinyl leukotriene receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is zafirlukast?
zafirlukast (ZAFIRLUKAST) is a cysteinyl leukotriene receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for zafirlukast?
ZAFIRLUKAST is a marketed brand name for zafirlukast. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zafirlukast?
zafirlukast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.